REG - Sareum Holdings PLC - Update on SRA737

Sareum HoldingsAnnouncement

12/10/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221012:nRSL5585Ca&default-theme=true

RNS Number : 5585C  Sareum Holdings PLC  12 October 2022

Sareum Holdings PLC

("Sareum" or the "Company")

Update on SRA737

 

Cambridge, UK, 12 October 2022 - Sareum Holdings plc (AIM: SAR), a clinical
stage biotechnology company developing next generation kinase inhibitors for
autoimmune disease and cancer, announces that it has been informed by Sierra
Oncology, Inc. ("Sierra") (a subsidiary of GSK plc ("GSK") that it intends to
return the rights for SRA737 to the CRT Pioneer Fund LP ("CPF").

SRA737, a clinical-stage oral, selective Checkpoint kinase 1 inhibitor that
targets cancer cell replication and DNA damage repair mechanisms, was
discovered and initially developed by scientists at The Institute of Cancer
Research in collaboration with Sareum, with funding from Sareum and Cancer
Research UK.

Sareum will discuss actively with CPF the potential options for future
development opportunities for SRA737 and evaluate its next steps accordingly.

CPF acquired worldwide commercial rights to the programme in 2013 as part of a
co-development agreement with Sareum. SRA737 was licensed by CPF to Sierra in
September 2016. Sierra progressed SRA737 through Phase 1/2 clinical
development and, at the 2019 ASCO Annual meeting, reported positive
preliminary efficacy and safety data from two clinical trials evaluating
SRA737 as a monotherapy and in combination with chemotherapy. In addition,
preclinical data have been reported that indicate triple drug combinations
involving SRA737 may show great promise against hard-to-treat cancers. Sierra
has not progressed the asset beyond the Phase 1/2 clinical trial.

Sierra was acquired by GSK in July 2022.

Dr Tim Mitchell, CEO of Sareum, commented:

"We continue to believe that SRA737 has great potential in several oncology
applications, and Sareum now has the opportunity to be involved in planning
its future development, supported by the positive clinical studies previously
undertaken by Sierra.

"Sareum has a strong pipeline of kinase inhibitors on the threshold of
clinical development. Subject to regulatory approval, we plan to advance our
lead candidate SDC-1801 into clinical development shortly, a significant
milestone for our business. With a strong pipeline and increased clinical
validation around the JAK kinase space, we are optimistic about the potential
of this drug class, both for patients and commercially."

- Ends -

For further information, please contact:

 Sareum Holdings plc

 Tim Mitchell, CEO                                   01223 497700

 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                         020 7409 3494

 Peel Hunt LLP (Joint Corporate Broker)

 James Steel                                         020 7418 8900

 Hybridan LLP (Joint Corporate Broker)

 Claire Noyce                                        020 3764 2341

 Consilium Strategic Communications (Financial PR)

 Jessica Hodgson / Davide Salvi / Stella Lempidaki   0203 709 5700

 

The information contained within this announcement is deemed to constitute
inside information as stipulated under the Market Abuse Regulations (EU) No.
596/2014, which is part of UK law by virtue of the European Union (Withdrawal)
Act 2018.

About Sareum

Sareum Holdings (AIM:SAR) is a clinical stage biotechnology company
developing next generation kinase inhibitors for autoimmune disease and
cancer.

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC 1801, simultaneously inhibits TYK2 and JAK1. SDC1801
is a potential treatment for a range of autoimmune diseases, which has entered
clinical development with an initial focus on psoriasis. Sareum is also
developing SDC1802, a TYK2/JAK1 inhibitor with a potential application for
cancer immunotherapy.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange,
trading under the ticker SAR. For further information, please visit the
Company's website at www.sareum.com (http://www.sareum.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDBFLLFLBLBFBQ